Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,045 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Congenital Anemias Clear all
Completed Not applicable Interventional

Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

NCT00068523
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, UV light therapy, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 20, 2026, 4:54 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

NCT06546670
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
ITU512, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 55 Years
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
9
States / cities
Birmingham, Alabama • Miami, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 20, 2026, 4:54 PM EDT
Terminated Phase 2 Interventional Results available

Treatment of Hemoglobin SC Disease With Hydroxyurea

NCT02336373
View directory record Official record
Conditions
Hemoglobin SC Disease
Interventions
hydroxyurea
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
5 Years to 21 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 20, 2026, 4:54 PM EDT
Terminated Phase 1Phase 2 Interventional

A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease

NCT04335721
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Nephropathy
Interventions
Voxelotor
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 20, 2026, 4:54 PM EDT
Terminated Not applicable Interventional Results available

Bi-Level Positive Airway Ventilation for Acute Chest Syndrome

NCT01589926
View directory record Official record
Conditions
Sickle Cell Anemia, Acute Chest Syndrome
Interventions
Bi-level positive airway pressure device, Sham CPAP
Device
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
4 Years to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 20, 2026, 4:54 PM EDT
Completed Not applicable Interventional

Mindfulness-Based Intervention for Pain and Sleep in Adolescents and Young Adults With Sickle Cell Disease

NCT07402811
View directory record Official record
Conditions
Chronic Pain, Sickle Cell Disease, Sleep Disturbance
Interventions
Mobile bindfulness-based intervention
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
15 Years to 39 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 20, 2026, 4:54 PM EDT
Completed Phase 2 Interventional

Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias

NCT00061763
View directory record Official record
Conditions
Beta-thalassemia, Myelodysplastic Syndromes, Fanconi Syndrome, Anemia, Diamond-Blackfan, Anemia, Aplastic
Interventions
Deferasirox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
6
States / cities
Oakland, California • Stanford, California • Arlington Heights, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 20, 2026, 4:54 PM EDT
Completed No phase listed Observational

Disseminating NIH Evidence Based Sickle Cell Recommendations in North Carolina

NCT03253211
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
4,392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 20, 2026, 4:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Collection of Blood From Persons With Hemoglobin and Erythrocyte Polymorphisms for Laboratory Malaria Research

NCT00277849
View directory record Official record
Conditions
Hemoglobin Mutations, Erythrocyte Variants
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 20, 2026, 4:54 PM EDT
Completed Phase 2 Interventional Results available

Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

NCT01392989
View directory record Official record
Conditions
Neural Tube Defects, Anemia, Leukemia, Myeloid, Bone Marrow Transplant Failure, Myelodysplastic Syndromes (MDS), Myeloproliferative Disorders
Interventions
CIK cells, Cyclosporine, Mycophenolate Mofetil, Thymoglobulin, Total Lymphoid Irradiation (TLI)
Drug · Radiation
Lead sponsor
Everett Meyer
Other
Eligibility
50 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 20, 2026, 4:54 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)

NCT04853576
View directory record Official record
Conditions
Sickle Cell Disease, Hemoglobinopathies
Interventions
EDIT-301
Genetic
Lead sponsor
Editas Medicine, Inc.
Industry
Eligibility
12 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
21
States / cities
Oakland, California • Aurora, Colorado • New Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 20, 2026, 4:54 PM EDT
Completed Phase 1 Interventional

Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease

NCT01522547
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
pomalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 20, 2026, 4:54 PM EDT
Completed Not applicable Interventional

Blood Cell Collection for Future Use in Individuals With Fanconi Anemia

NCT00271089
View directory record Official record
Conditions
Fanconi Anemia
Interventions
PBSC Collection, Bone Marrow Harvest, CliniMacs Cell Selection System
Procedure · Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
1 Year to 35 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 20, 2026, 4:54 PM EDT
Completed Phase 3 Interventional

Hydroxyurea Optimization Through Precision Study

NCT03789591
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Interventions
Hydroxyurea
Drug
Lead sponsor
Lifespan
Other
Eligibility
6 Months to 21 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
13
States / cities
Phoenix, Arizona • Atlanta, Georgia • Peoria, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 20, 2026, 4:54 PM EDT
Completed Not applicable Interventional

Laser Photocoagulation in Twin to Twin Transfusion Syndrome

NCT02506049
View directory record Official record
Conditions
Twin to Twin Transfusion Syndrome
Interventions
S-LPC:Selective Laser Photocoagulation
Device
Lead sponsor
University of Tennessee
Other
Eligibility
16 Weeks to 27 Weeks · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
2
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 20, 2026, 4:54 PM EDT
Completed Phase 1 Interventional

Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD)

NCT01783691
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
NKTT120
Drug
Lead sponsor
NKT Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
6
States / cities
Oakland, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 20, 2026, 4:54 PM EDT
Withdrawn Not applicable Interventional

Iron Prophylaxis for Anemia in Infants With Cyanotic Congenital Heart Disease

NCT00459225
View directory record Official record
Conditions
Anemia
Interventions
Iron (ferrous sulfate)
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 2 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Oct 20, 2026, 4:54 PM EDT
Completed No phase listed Observational

Improving Emergency Department Management of Adults With Sickle Cell Disease

NCT01603160
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Quality Improvement
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Oct 20, 2026, 4:54 PM EDT
Recruiting No phase listed Observational

Investigation of the Genetics of Hematologic Diseases

NCT02720679
View directory record Official record
Conditions
Bone Marrow Failure Syndromes, Erythrocyte Disorder, Leukocyte Disorder, Hemostasis, Blood Coagulation Disorder, Sickle Cell Disease, Dyskeratosis Congenita, Diamond-Blackfan Anemia, Congenital Thrombocytopenia, Severe Congenital Neutropenia, Fanconi Anemia, Myelodysplastic Syndromes, Myeloproliferative Diseases
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
1,716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2050
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 20, 2026, 4:54 PM EDT
Terminated No phase listed Observational

Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO)

NCT04964323
View directory record Official record
Conditions
Pyruvate Kinase Deficiency, Pyruvate Kinase Deficiency Anemia, Anemia, Anemia, Hemolytic
Interventions
Not listed
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 20, 2026, 4:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants

NCT06813924
View directory record Official record
Conditions
Healthy Volunteers Sickle Cell Disease, Thalassemia
Interventions
Etavopivat, Digoxin, Pitavastatin, Metformin, Midazolam, Rosuvastatin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 20, 2026, 4:54 PM EDT
Completed Phase 3 Interventional

Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)

NCT01737814
View directory record Official record
Conditions
Vaso-occlusive Crisis, Sickle Cell Disease
Interventions
Saline, MST-188
Drug
Lead sponsor
Mast Therapeutics, Inc.
Industry
Eligibility
4 Years to 65 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
50
States / cities
Mobile, Alabama • Phoenix, Arizona • Oakland, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 20, 2026, 4:54 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Sickle Cell Disease and the Genomic and Gene Therapy Needs of Stakeholders

NCT04416178
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
13 Years and older
Enrollment
352 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 20, 2026, 4:54 PM EDT
Completed Phase 1Phase 2 Interventional

Stem Cell Gene Therapy for Sickle Cell Disease

NCT02247843
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
βAS3-FB vector transduced peripheral blood CD34+ cells
Biological
Lead sponsor
Donald B. Kohn, M.D.
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 20, 2026, 4:54 PM EDT